Sorafenib Tablets

Product Description

Sorafenib is a medication used in the treatment of certain types of cancer, particularly advanced kidney cancer (renal cell carcinoma) and advanced liver cancer (hepatocellular carcinoma). It is available in tablet form, typically in strengths of 200 mg. Here's an overview of its use:

1. Renal Cell Carcinoma Sorafenib is approved for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It is used in patients who have not responded to previous treatments or who are not candidates for other therapies.

2. Hepatocellular Carcinoma Sorafenib is also used in the treatment of advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. It is indicated for patients with advanced HCC who are not eligible for surgical resection or transplantation and who have not responded to other treatments.

Sorafenib is a multikinase inhibitor, which means it works by inhibiting several enzymes involved in cancer cell growth and proliferation, as well as in tumor angiogenesis (the formation of new blood vessels that tumors need to grow). By blocking these pathways, sorafenib helps slow down the progression of cancer and may prolong survival in some patients.

The standard dose of sorafenib for both renal cell carcinoma and hepatocellular carcinoma is typically 400 mg (two tablets of 200 mg) taken orally twice daily. It's important to take sorafenib exactly as prescribed by a healthcare professional and to follow all instructions provided with the medication.

Common side effects of sorafenib may include diarrhea, fatigue, hypertension (high blood pressure), hand-foot skin reaction (palmar-plantar erythrodysesthesia), rash, nausea, and decreased appetite. It's essential for patients to be monitored closely by their healthcare provider while taking sorafenib to manage any side effects and ensure the treatment remains effective.

As with any cancer treatment, it's crucial to discuss the potential benefits and risks of sorafenib with a healthcare professional to make informed decisions about treatment options.

Powerful Targeted Cancer Therapy

Sorafenib Tablets deliver a cutting-edge approach to treating selected cancers by targeting cancer cells and inhibiting their growth. Approved by regulatory agencies such as US FDA and EMA, this oral therapy provides precision against hepatocellular, renal, and thyroid carcinomas, improving patient outcomes through advanced pharmaceutical science.


Convenient Oral Administration

Designed for patient ease, Sorafenib is administered orally as a film-coated tablet. The 200 mg dosage enables clear and consistent drug delivery, streamlining treatment regimens for individuals who require ongoing cancer therapy in an outpatient setting.